While the AE profile in the current study varied by treatment arm, with a slightly larger incidence of grade 3–4 neutropenia and thrombocytopenia within the G-CHP arm compared to the R-CHP arm [18], exposures of acMMAE and unconjugated MMAE in both arms were similar at the 1.8-mg/kg dose level of pola. The gene discussed is POLA1; the disease is Thrombocytopenia.